The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties

Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory e...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhijie, Yan, Yuanliang, Li, Zhi, Qian, Long, Gong, Zhicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133451/
https://www.ncbi.nlm.nih.gov/pubmed/27994551
http://dx.doi.org/10.3389/fphar.2016.00473
_version_ 1782471265497382912
author Xu, Zhijie
Yan, Yuanliang
Li, Zhi
Qian, Long
Gong, Zhicheng
author_facet Xu, Zhijie
Yan, Yuanliang
Li, Zhi
Qian, Long
Gong, Zhicheng
author_sort Xu, Zhijie
collection PubMed
description Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to be discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG.
format Online
Article
Text
id pubmed-5133451
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-51334512016-12-19 The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties Xu, Zhijie Yan, Yuanliang Li, Zhi Qian, Long Gong, Zhicheng Front Pharmacol Pharmacology Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to be discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG. Frontiers Media S.A. 2016-12-02 /pmc/articles/PMC5133451/ /pubmed/27994551 http://dx.doi.org/10.3389/fphar.2016.00473 Text en Copyright © 2016 Xu, Yan, Li, Qian and Gong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xu, Zhijie
Yan, Yuanliang
Li, Zhi
Qian, Long
Gong, Zhicheng
The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title_full The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title_fullStr The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title_full_unstemmed The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title_short The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
title_sort antibiotic drug tigecycline: a focus on its promising anticancer properties
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133451/
https://www.ncbi.nlm.nih.gov/pubmed/27994551
http://dx.doi.org/10.3389/fphar.2016.00473
work_keys_str_mv AT xuzhijie theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT yanyuanliang theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT lizhi theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT qianlong theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT gongzhicheng theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT xuzhijie antibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT yanyuanliang antibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT lizhi antibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT qianlong antibioticdrugtigecyclineafocusonitspromisinganticancerproperties
AT gongzhicheng antibioticdrugtigecyclineafocusonitspromisinganticancerproperties

Ejemplares similares